136.33
+0.24%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhangzhou Pientzehuang Pharmaceutical Co
Its shares trade on Shanghai under the ticker 600436.SS. It has been listed since 16 June 2003. In the fiscal year to 31 December 2025, it reported revenue of CN¥9.00bn and net income of CN¥2.16bn. At that date it held total assets of CN¥17.56bn and shareholders' equity of CN¥14.54bn.
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. engages in the manufacture and sale of Chinese medicines. The company is headquartered in Zhangzhou, Fujian. The company went IPO on 2003-06-16. The firm is also engaged in the production and sales of cosmetics and daily chemical products and the circulation of medicine. The firm's core products are PianZi Huang series products, including PianZi Huang, PianZi Huang capsule, compound PianZi Huang buccal tablets, compound PianZi Huang ointment, compound PianZi Huang hemorrhoids ointment and others, covering many fields such as liver disease medication, cold medication, dermatology medication. The firm's products are sold to domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 Jun 2003
- Employees
- 2,720
- Website
- zzpzh.com ↗
Leadership
Pay as last reported
- Mr. Zhihui LinChairman of the Board, since 2023CN¥234,800
- Mr. Haipeng YangChief Accounting Officer, Director, since 2019CN¥495,900
- Mr. Jinming HuangGeneral Manager, Director, since 2006CN¥563,500
- Mr. Yixiong ShiDeputy General Manager, Acting Secretary of the Board
- Mr. Zexiu ZhangDeputy General ManagerCN¥583,900
- Mr. Wenning LaiDirector
- Ms. Lei ChenIndependent Director
- Ms. Shouying DuIndependent DirectorCN¥80,000
- Mr. Zhipeng FanIndependent DirectorCN¥80,000
- Mr. Lei ZhangIndependent DirectorCN¥40,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 80
- Environment
- 96
- Social
- 72
- Governance
- 72
- Direct emissions (scope 1)
- 2,222.63 t
- Energy emissions (scope 2)
- 6,787.3 t
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhangzhou Pientzehuang Pharmaceutical Co Ltd has a strong presence in the Chinese medicine sector with core products like PianZi Huang series products.
- The company employs 2720 full-time employees, supporting its operations in Zhangzhou, Fujian.
- Zhangzhou Pientzehuang Pharmaceutical Co Ltd has been publicly traded since its IPO on June 16, 2003.
Weaknesses
- The company's product line is limited to the PianZi Huang series products and related pharmaceuticals.
- Zhangzhou Pientzehuang Pharmaceutical Co Ltd operates primarily within the Chinese market, with limited international presence.
- The company's operations are concentrated in Zhangzhou, Fujian, which may restrict its geographic expansion.
Opportunities
- The firm's core products cover liver disease medication, cold medication, and dermatology medication, offering potential for market expansion in these segments.
- Zhangzhou Pientzehuang Pharmaceutical Co Ltd can leverage its existing product portfolio to enter new markets for cosmetics and daily chemical products.
- The company's website https://www.zzpzh.com/ provides a platform for expanding its online presence and customer engagement.
Threats
- The company faces competition in the Chinese medicine sector from other pharmaceutical firms in Fujian.
- Zhangzhou Pientzehuang Pharmaceutical Co Ltd's reliance on the PianZi Huang series products could be a vulnerability if market preferences shift.
- The firm's operations in Zhangzhou, Fujian may be affected by regional economic or regulatory changes in the Fujian province.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.